Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadically or in the context of neurofibromatosis type 1. Epidermal growth factor receptor (EGFR) overexpression has been implicated in MPNST formation, but its precise role and relevant signaling pathways remain unknown. We found that EGFR overexpression promotes mouse neurofibroma transformation to aggressive MPNST (GEM-PNST). Immunohistochemistry demonstrated phosphorylated STAT3 (Tyr705) in both human MPNST and mouse GEM-PNST. A specific JAK2/STAT3 inhibitor FLLL32 delayed MPNST formation in an MPNST xenograft nude mouse model. STAT3 knockdown by shRNA prevented MPNST formation in vivo. Finally, reducing EGFR activity strongly reduced pSTAT3 in vivo. Thus, an EGFR-STAT3 pathway is necessary for MPNST transformation and establishment of MPNST xenografts growth but not for tumor maintenance. Efficacy of the FLLL32 pharmacological inhibitor in delaying MPNST growth suggests that combination therapies targeting JAK/STAT3 might be useful therapeutics.
INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive incurable sarcomas that arise in 0.001% of the general population. However, the incidence of MPNST increases to 8-13% in neurofibromatosis type 1 (NF1) patients. [1] [2] [3] [4] In NF1, benign peripheral nerve plexiform and subcutaneous neurofibromas can undergo malignant transformation to MPNSTs. 5, 6 MPNSTs are a major source of mortality for NF1 patients because only complete surgical resection is curative and complete resection is often not feasible due to tumor location or metastasis. MPNST patients are often not sensitive to chemotherapy or radiation therapy. 1, 7 MPNSTs derive from either neural crest cells or glial cells that dedifferentiate to a neural crest-like cell. [8] [9] [10] [11] Hyperactive Ras, resulting from the loss function of neurofibromin, is a major contributor of Schwann cells malignant transformation to MPNST. Indeed, mass spectroscopy-based analysis of an MPNST cell line failed to detect mutations in 19 commonly activated oncogenes. 12 Epidermal growth factor receptor (EGFR or erbB1) is a 170-kDa transmembrane tyrosine kinase, which triggers signaling processes that promote cell proliferation, migration, adhesion and angiogenesis, and inhibits apoptosis. 13 While peripheral nerve Schwann cells that might be cells of origin of MPNST do not express EGFR, Schwann cell progenitors and MPNST cells do (see DeClue et al. 14 and Li et al. 15 ). EGFR is expressed in 80% of human MPNSTs, and most human and mouse MPNST cell lines. [14] [15] [16] [17] [18] EGFR is deregulated in a variety of solid malignant tumors by overexpression of EGFR protein, activating point mutations in the tyrosine kinase domain, or other mutations. In NF1, EGFR is overexpressednot activated by mutation. 16, 18 In a compound cis-heterozygous Nf1 and p53 (NPcis) mouse sarcoma model, 9 ,10 loss of EGFR function by breeding the NPcis mouse to a mouse carrying an EGFR hypomorphic mutation Wa2 (Wa2 þ ) 19 resulted in delayed sarcoma formation. 20 Taken together, the data support a role for EGFR in MPNSTs. It is unclear, however, whether EGFR is sufficient or necessary for MPNST malignant transformation and/or tumor maintenance. Signal transducer and activator of transcription 3 (STAT3) is a latent transcription factor that participates in transcriptional activation of apoptosis and cell-cycle progression, and has been implicated as an oncogene and therapeutic target in neoplastic disease.
21 STAT3 phosphorylation at (Tyr705) is essential for STAT3 dimerization that, in turn, is required for STAT3 binding to DNApromoter regions and, thus, transcriptional activation. 22 The EGFR-src-STAT3 oncogenic pathway is involved in cell transformation and tumor escape from genotoxic treatment. 23 STAT3 also regulates self-renewal and growth of glioblastoma stem cells. 24 
STAT3 is hyperactivated in Nf1
À / À primary astrocytes and STAT3 inhibition by cucurbitacin-I blocked human MPNST growth in vivo when delivered for 7 days at onset of cell xenograft. 25 Whether EGFR-dependent STAT3 activation plays a role in MPNST transformation is unknown. Here, we report that EGFR overexpression in a neurofibroma mouse model is sufficient to promote neurofibroma transformation into mouse MPNST (GEM-PNST). STAT3 (Tyr705) was hyperphosphorylated in mouse GEM-PNSTs and human MPNSTs, and inhibition of STAT3 with the specific JAK2/ STAT3 inhibitor FLLL32, which blocks STAT3 activity by both blocking STAT3 dimerization and JAK2 interaction with STAT3, 26 delayed MPNST xenograft formation in nude mice. Short-hairpin RNA targeting STAT3 (shSTAT3) prevented MPNST xenograft tumor formation in vivo. These data support a role for the EGFR-STAT3 pathway in MPNST transformation, but not in tumor maintenance. 1 fl/fl ;DhhCre;CNP-hEGFR mice developed neurofibromas. Surprisingly, five mice (33.3%) developed visible tumors at 4-8 months of age. These tumors were rapidly growing and either under or protruding through the skin; the protruding tumors sometimes exhibited surface ulceration (Figure 1a) . The histological and immunohistochemical features of the rapidly growing tumors are consistent with GEM-grade III PNST. 28 In one tumor, we detected a transition zone of neurofibroma (low-tomoderate cellularity and nuclear atypia of rare cells, scattered S100b þ cells (Figures 1c, d and f) ) to densely cellular tumor GEM-PNST characterized by spindle-shaped cells with numerous mitotic figures and foci of necrosis (Figures 1c and e) . In addition, all GEMPNSTs showed association between nerves and scattered S100b þ cells (Figure 1g ), typical of GEM-grade III PNSTs. All GEM-grade III PNST tumors expressed the human EGFR transgene (6 of 6) ( Figure 1h ). The results suggest that GEM-grade III PNSTs developed from pre-existing neurofibromas.
RESULTS

Overexpression of
STAT3 is activated in human MPNSTs and mouse GEM-PNSTs If pathways upstream of STAT3 regulate MPNST growth, pSTAT3 should be detected in these peripheral nerve tumors. We therefore labeled paraffin sections of human MPNSTs and mouse GEM-PNSTs with antibodies that recognize the major STAT3 phosphorylation sites. Tyrosine 705 is necessary for STAT3 dimerization and translocation to the nucleus. Immunopositive staining for pSTAT3 (Tyr705) was detected in all human MPNSTs (n ¼ 15) and mouse GEM-PNSTs (n ¼ 6) (Figures 2a and b) . The percentage of cells expressing pSTAT3 (Tyr705) varied among tumors (from o25% to 475%, Figure 2c ). In contrast, detectable levels of pSTAT3 (Ser727) were found in only one of four mouse GEM-PNSTs, and only two of four human MPNSTs (data not shown).
JAK2/STAT3 inhibition prevents MPNST cells growth in vitro
To test if STAT3 or the Stat kinases JAK 1, 2 or 3 is relevant to MPNST cell growth, we screened JAK and JAK2/STAT3 inhibitors. We conducted a dose-response analysis of FLLL32, a specific JAK2/ STAT3 inhibitor 26 Figure 1A) . We performed western blots on lysates from inhibitor treated 8814 and S462TY cells. All the inhibitors inhibited pSTAT3 and pJAK2, but none of them affected pERK except CP690550 (Supplementary Figures 1C and D) . These results suggest that JAK1/2-mediated STAT3 signaling contributes to MPNST cell survival. Due to the unavailability of a specific JAK1 inhibitor, we could not differentiate if the survival effect was caused by JAK1 or JAK2, or both. However, together with the JAK2/STAT3 inhibitor FLLL32 results, we concluded that JAK2/STAT3 inhibition can prevent MPNST cell growth.
Pharmacological inhibition of STAT3 delays MPNST growth in vivo
We tested whether blocking the JAK2/STAT3 pathway might affect growth in an MPNST xenograft model. We treated nude mice when S462TY MPNST tumors were 4250 mm 3 (n ¼ 8), administering FLLL32 (200 mg/kg) by daily intraperitoneal injection. We euthenized the treated mice by 23 consecutive days of treatment when the tumor size reached 410% of the mouse body weight, and did not detect significant changes in tumor size compared with vehicle-treated controls (Figure 4a ). However, when we treated the nude mice with S462TY MPNST tumors beginning when tumors were small (average 50 mm 3 ) (n ¼ 10) with FLLL32 (200 mg/kg) daily, tumor formation was significantly delayed (B2 weeks) compared with vehicle-treated controls (n ¼ 12, Figure 4b , Po0.0001). These results suggest that STAT3 affects the early stage of MPNST tumor growth.
To determine how FLLL32 delays MPNST growth, mice treated with 200 mg/kg/day FLLL32 or vehicle control for 14 days (early group) when FLLL32 is effective or 56 days (late group) when tumors were resistant to FLLL32 were killed 1 h after the final dose. We performed western blot to determine pSTAT3 levels at day 21 (2 weeks after FLLL32 treatment) and day 56 (at the end of the experiment) with or without FLLL32 treatment. pSTAT3 was low at both time points, indicated that the drug is effective at both time points (Figure 4c ). We then analyzed cell death, cell proliferation and blood vessels in paraffin sections of excised MPNSTs by TUNEL and Ki67 staining, respectively. In the early group, the average percentage of TUNEL þ , dying cells was 9.6 ± 1.6% in FLLL32-treated MPNSTs vs 6.6 ± 0.6% in control (Po0.01, Figure 4d ). There was no significant difference in the percentage of Ki67 þ , proliferating cells in FLLL32-treated MPNSTs (33.7 ± 3.7%, n ¼ 5) compared with vehicle control (32.4 ± 3.2%, n ¼ 5) (P ¼ 0.28, Figure 4e ). In the late group, the average percentage of TUNEL þ , dying cells was 7.1±1.4% in FLLL32-treated MPNSTs vs 2.1±0.6% in control (Po0.01, Figure 4g ). There was no significant difference in the percentage of Ki67 þ , proliferating cells in FLLL32-treated MPNSTs (21.9 ± 4.3%, n ¼ 5) compared with vehicle control (26±2.7%, n ¼ 3) (P ¼ 0.21, Figure 4h ). We also analyzed the number of blood vessels per high power field by staining these tumors with the endothelial cell marker MECA 32. Interestingly, there was a decrease in blood vessels per high power field in the early stage of treatment group (P ¼ 0.04, Figure 4f) , and more effect in the late stage of treatment group (Po0.001, Figure 4i) , suggesting that decreased vasculature may also be involved in the drug treatment induced tumor cell death.
The efficacy of STAT3 only in early but not late stage is likely to involved factors other than proliferation, death or change in vasculature, such as initial establishment of tumors, change tumor cytokines or other factors.
STAT3 deficiency abrogates MPNST formation in vivo
With any chemical inhibitor, there is the potential for lack of specificity. Therefore, to confirm the role of STAT3 in MPNST, we transduced NF1 patient-derived S462TY MPNST cells with a lentivirus encoding shRNA targeting STAT3; a non-targeting shRNA also expressing YFP served as a control. Western blot analysis confirmed that STAT3 level was decreased after infection of MPNST cells with this vector, which did not change pAKT or pERK levels, indicating that other signaling pathways remain intact in shSTAT3-treated MPNST cells (Figure 5a ). MTS assay of shSTAT3- expressing cells revealed decreased numbers of viable cells, but in contrast to cells exposed to JAK/STAT3 inhibitors cleaved caspase-3 was not detectable, suggesting that these cells were not dying by apoptosis (data not shown). It is possible that targeting JAK as well as STAT with inhibitors causes a shift to apoptosis. We injected sh-non-target controls or shSTAT3 cells subcutaneously into nu/nu (nude) mice (n ¼ 6). Tumor growth was not detectable on the right sides of animals, injected with STAT3 shRNA-expressing MPNST cells (Figure 5b, arrowhead) . However, the left sides, which received the same number of non-target shRNA-expressing MPNST cells, exhibited significant tumor growth (Figure 5b , arrow). Mice were killed at day 64, when volumes of control non-target tumors reached allowable limits (Figure 5c ). These results confirm a key role for STAT3 in MPNST tumor formation in xenografts.
EGFR/JAK2/STAT3 activation contributes to MPNST transformation To determine if EGFR expression contributed to STAT3 (Tyr705) phosphorylation in vivo, we monitored STAT3 (Tyr705) phosphorylation in the NPcis mouse GEM-PNST compared with NPcis;Wa2/ þ mouse GEM-PNSTs. 20 pSTAT3 decreased significantly in NPcis; Wa2/ þ mouse GEM-PNSTs (n ¼ 4, Figure 6b ), compared with NPcis mouse GEM-PNSTs (n ¼ 4, Figures 6a and c, Po0.001) . Western blots confirmed decreased pJAK2, total JAK2 (tJAK2) and pSTAT3 in NPcis;Wa2/ þ mouse GEM-PNST tumors compared with the NPcis GEM-PNSTs (Figure 6d) , suggesting that the decrease of pSTAT3 (Tyr 705) is caused at least in part by JAK2, but we cannot exclude the possibility that the STAT3 is directly phosphorylated and activated by EGFR. To determine if EGFR expression correlates with STAT3 (Tyr705) phosphorylation, we stimulated serum-starved 8814 cells with EGF (20 ng/ml) for 10 min and monitored pEGFR and pSTAT3 (Tyr705) levels. Both EGFR and STAT3 (Tyr705) were robustly phosphorylated in the EGF-stimulated cells (Figure 6e) . In 8814 cells treated with the EGFR tyrosine kinase inhibitor OSI-774, pSTAT3 (Tyr705) decreased correlated with pEGFR level (Figure 6f ). These gain and loss of function of EGFR results demonstrate that EGFR is a significant activator of STAT3 in MPNST cells.
DISCUSSION
We found that increasing EGF receptor level in Nf1 peripheral nerve glial cells is sufficient to promote the transformation of benign neurofibroma to aggressive GEM-PNST, the counterpart of human MPNST. Activated STAT3 was prominent in human MPNSTs and mouse GEM-PNSTs, and a JAK2/STAT3 inhibitor delayed the growth of MPNST in nude mice. Furthermore, EGFR provided a major input to STAT3 activation in vitro and in vivo. The data support the hypotheses that STAT3 contributes to MPNST transformation but in spite of effects vasculature and tumor cell survival, is not necessary for tumor growth in established MPNST.
One-third of Nf1 fl/fl ;DhhCre CNP-hEGFR mice developed GEM-PNST. All Schwann cell in the CNP-hEGFR mouse nerve express EGFR 20 and all the GEM-PNST tumor cells express hEGFR ( Figure 1h) ; therefore, we infer co-expression of Nf1 and EGFR in the target cells. It is likely that additional events must occur in these cells to promote transformation to GEM-PNST, accounting for the low penetrance of aggressive tumors in this model. This is consistent with the numerous genetic changes in human MPNSTs. 29 Our data support a role for EGFR expression levels early (e, h) FLLL32 has no effect on inhibiting S462 TY MPNST cell proliferation at both early (e) or late (h) stage. (f, i) FLLL32 has no significant effect on blood vessel number at early stage (f ), but has significant difference in number of blood vessels at later stage (i) compared with vehicle controls. . A role for EGFR expression levels in early sarcoma formation could explain why EGFR expression levels in resected MPNST are not prognostic. 18 Our gain-of-function data in genetically engineered mice also suggest that the increased levels of EGFR might serve as a modifier predisposing to MPNST formation. Studies searching for modifiers of Nf1 GEM-PNST identified a locus on mouse chromosome 11, close to Egfr. [30] [31] [32] However, modifier effects might also derive from increased expression of EGFR ligands or EGFR ligand proteases, and/or increased expression of other pathway genes.
STAT3 is known to act as an oncogene, initiating tumor formation and maintaining tumor cell proliferation in other tumor systems. 21 Consistent with these studies, our data support a key role for STAT3 in transformation of MPNST. In tissue culture, MPNST cells remained responsive to JAK and JAK2/STAT3 inhibitors, as they do to EGFR inhibitors. 7, 33 Ligand-bound, phosphorylated EGFR physically interacts with the SH2 domain of STAT3-leading to phosphorylation of STAT3 at Tyr705, STAT3 dimerization, translocation to the nucleus and STAT3-activated gene transcription. 34 EGFR and phosphorylated STAT3 (Tyr705) are co-expressed in many cancers. [35] [36] [37] [38] In human MPNST and mouse GEM-PNSTs, STAT3 was phosphorylated at Tyr705, and STAT3 phosphorylation was robust in all MPNST tissue sections. In contrast, STAT3 was phosphorylated at Ser727 in only a low percentage of cells, and in o20% of tested human and mouse tumors. A recent in vitro study found STAT3 phosphorylated on Ser727 in an MPNST cell line. 25 Thus, while Ser727 may be relevant in some rare tumors, STAT3 (Tyr705) is more consistently phosphorylated in and relevant to MPNSTs. EGFR signaling pathways induce epithelial-mesenchymal transition via STAT3-mediated TWIST gene expression in breast cancer. 39 Therefore, it is perhaps significant that TWIST is frequently overexpressed in MPNST. 29, 40 STAT3 is a potential therapeutic target, since blocking it with shRNA or the non-specific inhibitor curcumin inhibits growth in several cancer models. 25, [35] [36] [37] [38] Use of the specific JAK2/ STAT3 inhibitor, FLLL32, and/or its derivatives, should enable future clinical testing.
In summary, EGFR promotes MPNST formation via JAK2/STAT3 activation. Pharmacologic inhibition of JAK2/STAT3 using FLLL32 delays MPNST growth, and shSTAT3 eliminates MPNST formation. These data suggest that the EGFR-STAT3 axis contributes to MPNST initiation. However, once tumors become established, they no longer respond to EGFR or STAT3 inhibition.
MATERIALS AND METHODS Animals
Mice were housed in temperature-and humidity-controlled facilities on a 12-h dark-light cycle with free access to food and water. The animal care and use committees of Cincinnati Children's Hospital Medical Center or University of Minnesota approved all animal procedures. C57Bl/6 CNPhEGFR transgenic mice (CNP-hEGFR/ þ ) 20 were interbred to obtain homozygous mice (CNP-hEGFR/CNP-hEGFR). Cell culture MPNST cell lines included T265, ST8814, S462, S462TY (derived from the S462 cell line 41 by two rounds of in vivo growth as xenografts), and STS26T were maintained in Dulbecco's Modified Eagle Medium (DMEM)/10% fetal bovine serum (FBS)/1% penicillin/streptomycin. For drug treatment, inhibitors were added 2 h after plating of cells. MTS assays were performed at day 4 as described. 40 For EGF stimulation assays, 80% confluent of ST8814 cells were serum-starved overnight, EGF (20 ng/ml) was added for 10 min and the cells were collected for western blot analysis. For OSI-774 inhibition assays, ST8814 cells were treated with OSI-774 (3.3 mM) for 48 h and then collected for western blot analysis. Dimethyl sulfoxide (DMSO) (0.1%) was used as control. Primary human Schwann cells were the gift of Patrick Wood Miami Project to the Paralysis, and were cultured as described. 
Lentiviral infection
We infected S462TY cells at 60% confluence with shSTAT3 or non-target control (Sigma, St Louis, MO, USA). We incubated lentiviral particles with MPNST cells in the presence of polybrene (8 mg/ml; Sigma-Aldrich) daily for 3 days, followed by selection in puromycin (2.5 mg/ml; Sigma-Aldrich). Surviving cells were collected for xenograft injection.
Mouse xenografts
We injected 2.3 Â 10 6 S462TY MPNST cells in a total volume of 150 ml of 30% Matrigel (BD Biosciences, San Jose, CA, USA) into flanks of 5-to 6-week-old female athymic nude (nu/nu) mice (Harlan, Indianapolis, IN, USA); right flanks were injected with shSTAT3 cells, and left with non-target control cells. Tumor volume was calculated as L Â W 2 (p/6), where L is the longest diameter and W is the width. Tumors were dissected 1 h after last dose and immediately flash frozen in liquid nitrogen for biochemistry or fixed in 4% paraformaldehyde for histology.
Western blots
Tumor proteins were extracted using extraction buffer (20 mM NaPO 4 , 150 mM NaCl, 2 mM MgCl 2 , 0.1% Nonidet P-40, 10% glycerol, 10 mM sodium fluoride, 0.1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM phenylasine oxide, 10 nM okadaic acid, 1 mM dithiothreitol, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 10 mg/ml tosyl-L-phenylalanine chloromethyl ketone and 10 mg/ml N a -tosyl-L-lysine chloromethyl ketone). Protein concentration was estimated using Coomassie Plus Protein Assay Reagent. Proteins (40 mg/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 4-20% tris-glycine gel (Invitrogen, Carlsbad, CA, USA) and electrotransferred to polyvinylidene diflouride membrane. Membranes were blocked with 5% nonfat milk þ 0.1% TBST to minimize non-specific binding. Antibodies recognizing EGFR, pJAK2, JAK2, pSTAT3, STAT3, pERK, ERK and b-actin (Cell Signaling, Danvers, MA, USA) were used. Antibody binding to the membrane was visualized using a chemiluminescent detection system (ECL, Amersham, Arlington Heights, IL, USA). The bands obtained were quantified by Gel-pro analyzer (Media Cybernetics, Inc, Rockville, MD, USA). Anti-b-actin was used as a loading control. At least three different tumor lysates were analyzed for each antigen.
